Month: March 2026

Conference Call to be Held Thursday, March 26, 2026 at 10:00 a.m. Eastern Time QUINCY, Mass., March 25, 2026 (GLOBE NEWSWIRE) — Stran & Company, Inc. (“Stran” or the “Company”) (NASDAQ: SWAG) (NASDAQ: SWAGW), a leading outsourced marketing solutions provider that leverages its promotional products and loyalty incentive expertise, today announced its financial results for the fiscal year ended December 31, 2025, and provided a business update. Management will host a conference call at 10:00 a.m. Eastern Time on Thursday, March 26, 2026. 2025 Financial HighlightsSales: $116.2 million, an increase of 40.6% year-over-year EBITDA: $0.2 million, compared to $(3.6) million in 2024 and an improvement of $3.8 million Gross Profit: $34.2 million, representing a gross margin of 29.5% Cash, Cash Equivalents, and...

Fourth Quarter 2025 Comparable Restaurant Sales Increased 6.6% System-WideFirst Quarter 2026 Comparable Restaurant Sales Increased Over 9% To Date BROOMFIELD, Colo., March 25, 2026 (GLOBE NEWSWIRE) — Noodles & Company (Nasdaq: NDLS) today announced financial results for the fourth quarter and fiscal year ended December 30, 2025, and provided a 2026 business outlook. Key highlights for the fourth quarter of 2025 compared to the fourth quarter of 2024 include:Total revenue increased 0.8% to $122.8 million from $121.8 million. Comparable restaurant sales increased 6.6% system-wide, including a 7.3% increase for company-owned restaurants and a 3.8% increase for franchise restaurants. Net loss was $6.8 million, or $1.16 loss per diluted share, compared to net loss of $9.7 million, or $1.70 loss per diluted share. Operating margin...

FAIRFAX, Va., March 25, 2026 (GLOBE NEWSWIRE) — WidePoint Corporation (NYSE American: WYY), a federally certified provider of Trusted Mobility Management (TM2) solutions, reported results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 and Recent Operational Highlights:34th consecutive quarter of positive Adjusted EBITDA 9th consecutive quarter of positive Free Cash Flow Awarded $1.3 million managed services contract with a leading bottler in the beverage industry Awarded $1.25 million task order under the Navy Spiral 4 Contract for the U.S. Army Secured estimated $40 million to $45 million SaaS contract to deliver FedRAMP-authorized ITMS platform for a major telecommunications carrier Awarded new CWMS 2.0 task order by U.S. Customs & Border Protection valued up to $27.5 millionFourth Quarter...

Quarterly Revenue Surges 36% as Gross Margin Expands to 69.8% LOUISVILLE, Ky., March 25, 2026 (GLOBE NEWSWIRE) — LogicMark, Inc. (OTC: LGMK) (the “Company”), a provider of personal safety and emergency response systems (PERS), health communications devices, and technology for the growing care and safety economy, today announced financial and operational results for the fourth quarter and year ended December 31, 2025. Fourth Quarter and Full Year 2025 Financial Highlights  Revenue: Fourth-quarter revenue increased 36% to $3.1 million. Full-year revenue increased 15% to $11.4 million. Revenue has increased year-over-year in six of the last seven quarters. Gross margin: Fourth quarter gross margin increased to 69.8%. Full-year gross margin remained strong at 66.8%. Operating expenses: Fourth quarter operating expenses increased modestly...

VANCOUVER, British Columbia, March 25, 2026 (GLOBE NEWSWIRE) — LEEF Brands, Inc. (CSE: LEEF) (OTCQB: LEEEF) (“LEEF” or the “Company”), a rapidly growing cannabis company, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 HighlightsRevenue of $8.3 million, an increase of 38.9% year-over-year Gross profit of $3.8 million, up 188.2% year-over-year Gross margin of 45.5%, an increase of 23.5 percentage points year-over-year Adjusted EBITDA of $1.0 million, compared to $(3.1) million in Q4 2024, an improvement of 131.9% year-over-year Free cash flow of $1.2 million, compared to $(1.6) million in Q4 2024, an improvement of 173.4% year-over-yearFull-Year 2025 and Second Half 2025 HighlightsRevenue of $34.8 million, an increase of 22.1% year-over-year, with H2 revenue...

Dose escalation for NKX019 advanced to 4 billion cells per dose on days 0, 3 and 7 for a total of 12 billion cells per cycle Initial clinical data from Ntrust-1 and Ntrust-2 targeted for presentation at a medical conference in 2026 Cash balance of $295.1 million on December 31, 2025, including cash, cash equivalents and investments, is expected to fund operations into 2029SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) — Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today reported financial results for the fourth quarter and year ended December 31, 2025.  “2025 was a year of strategic importance for Nkarta as we onboarded a clinical team with deep autoimmune experience, right-sized our workforce to be a responsible...

Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi™ generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Approximately 53,000 total prescriptions were filled for Emrosi™ during FY2025 Payer access for Emrosi™ available to over 100 million U.S. commercial lives Company to hold conference call today at 4:30 p.m. ET SCOTTSDALE, Ariz., March 25, 2026 (GLOBE NEWSWIRE) — Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the full year...

The U.S. Food and Drug Administration (“FDA”) accepted Celcuity’s New Drug Application (“NDA”) and granted Priority Review with a Prescription Drug User Fee Act (“PDUFA”) goal date of July 17, 2026, for gedatolisib in HR+/HER2-/PIK3CA wild-type (“WT”) advanced breast cancer (“ABC”) Results from PIK3CA WT cohort of Phase 3 VIKTORIA-1 study of gedatolisib regimens in HR+/HER2- ABC published in Journal of Clinical Oncology Topline results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 study are expected to be released in the second quarter of 2026 Management to host webcast and conference call today, March 25, 2026, at 4:30 p.m. EDTMINNEAPOLIS, March 25, 2026 (GLOBE NEWSWIRE) — Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial...